This is a buy for me especially at the current levels. My sister is one of the 100 or so subjects in the current study. She has had MS for about 10 years and the doctor that got her in the study says that he is truly amazed at the results they have received. It's in the press releases, but the reduction of relapses by the patients receiving the actual product dropped to almost nil. The study is still running for another year but short plays are possible on this stock also. It seems to swing $1.00 both ways on occasion.
However, if you are looking for a very promising treatment for MS (something new and revolutionary) this is it!